MEDICAL RESEARCH BLOG

INFORMATION FOR PATIENTS AND FAMILY MEMBERS
Dear reader, thank you for your interest in reading this page, which is intended for patients and family members of patients with Chronic Kidney Disease. In this section we use everyday language. The same information is presented elsewhere on this site in more technical language aimed primarily at health professionals.
What is Chronic Kidney Disease (CKD)?
Chronic Kidney Disease (abbreviated CKD) occurs when the kidneys are damaged and have difficulty performing all of their important functions for at least 3 months. It is this 3-month period that distinguishes CKD from Acute Kidney Injury, which develops suddenly, usually in hospitalized patients undergoing intensive treatment, and may be reversible with recovery of they kidney function (MayoClinic.org).
According to current KDIGO guidelines — global standards for evaluating and treating CKD — in their latest 2024 edition, the disease is classified according to three factors, abbreviated as CGA::
-
Cause
-
Glomerular Filtration Rate (GFR)
-
Albumin
What causes CKD?
There are multiple causes of Chronic Kidney Disease, but the most frequent worldwide are: Type 2 Diabetes Mellitus and Hypertension (high blood pressure). These two diseases cause about 60%–70% of CKD worldwide. Other causes include:
-
Renal hypoplasia (underdeveloped, small kidneys)
-
Nephrolithiasis (kidney stones)
-
Polycystic kidney disease (an inherited condition that causes cyst formation in the kidneys and accounts for about 5% of CKD)
-
Systemic lupus erythematosus and other autoimmune diseases (conditions where the body attacks its own kidneys)
-
Chronic use of pain and anti-inflammatory medications known as NSAIDs (ketorolac, naproxen, diclofenac, ketoprofen, ibuprofen, indomethacin, etc.)
-
Other uncommon diseases

What is albumin and how is it measured?
Albumin is our main protein found in the blood. It helps build muscles and tissues and fight infections (National Kidney Foundation). When albumin is found in the urine, it is called albuminuria or proteinuria, and it indicates that the kidneys are not functioning properly, because healthy kidneys prevent albumin from passing into the urine. Measuring albumin in urine is very important because it is a sign of kidney disease even when the GFR is still normal. Albuminuria is diagnosed with a urine test, and results are classified into three grades:
-
A1 - "Normal": Less than 30 mg/g per day
-
A2 - "Moderately elevated": Between 30 mg/g and 300 mg/g per day
-
A3 - "Very elevated": More than 300 mg/g per day
What is the Glomerular Filtration Rate (GFR)?
GFR tells us whether the kidneys are doing their job of filtering waste and excess water from the blood into the urine. Because not all stages of CKD cause symptoms, measuring GFR gives a quick idea of kidney health and helps detect disease in its early stages. GFR is obtained through a blood test that measures creatinine (a waste product of normal muscle breakdown) and calculates how much blood the kidneys can clear per minute. High creatinine levels in the blood indicate that the kidneys are having trouble filtering. Using GFR, the KDIGO guidelines classify CKD into five stages:
-
Stage 1: Normal GFR (greater than 90 mL/min/1.73m²) but with structural abnormalities, protein in the urine, or persistent blood in the urine for longer than 3 months
-
Stage 2: GFR between 60 and 90 mL/min/1.73m²
-
Stage 3: GFR between 30 and 60 mL/min/1.73m², further subdivided into:
-
Stage 3a GFR of 45 to 60
-
Stage 3b GFR of 30 to 45
-
It is important to emphasize that up to Stage 3b, the patient still has CKD but not Chronic Kidney Failure (CKF). In many of these patients, there are no symptoms, which is why CKD is often called a “silent disease” — people usually do not feel anything abnormal until later stages (Stages 4 and 5). CKD generally does not go away but progresses unless early treatment is provided to slow or stop the disease (WorldKidneyDay.org). This is why annual medical checkups are recommended to detect CKD and other diseases early. Progression eventually leads to End-Stage Renal Disease (ESRD), where dialysis or kidney transplant is needed to survive.
-
Stage 4 (CKF): GFR between 15 and 29 mL/min/1.73m² — kidneys have severely reduced function.
-
Stage 5 (CKF): GFR less than 15 mL/min/1.73m² — kidneys no longer clear waste effectively; this stage is also known as End-Stage Renal Disease (ESRD) and requires kidney replacement therapy
-- When CKD Becomes Chronic Kidney Failure --
When GFR falls below 30 mL/min/1.73m², the kidneys are no longer able to perform many vital functions, including:
-
Blood pressure control
-
Production of erythropoietin (stimulates red blood cell production)
-
Regulation of calcium, phosphorus, and electrolytes
-
Activation of vitamin D
-
Formation of normal urine
-
Elimination of toxic waste (ammonia, urea, uric acid, creatinine)
-
Metabolism and excretion of medications
Because of this loss of function, CKF patients often develop high blood pressure, anemia (due to lack of erythropoietin), bone fragility from low calcium and vitamin D, and other complications. In as little as 2 to 3 years, kidney function can decline from 30% down to 15%, causing serious symptoms such as fatigue, swelling, shortness of breath, and more, at which point urgent treatment is needed. This is why, it is extremely important to prevent and avoid the continuing deterioration, even when the kidneys work more than 50%.
Which are the symptoms of Chronic Kidney Failure?
In earlier stages of CKD (Stages 1–3) there may be no symptoms, but once CKF (Stages 4 and 5) develops, patients can experience symptoms that significantly affect quality of life. Common symptoms include:
-
Fatigue or generalized weakness (from toxin buildup and anemia)
-
Paleness (from anemia)
-
Swelling (from fluid retention)
-
Shortness of breath (from anemia and fluid buildup)
-
Foamy urine (from protein loss in urine)
-
Poor appetite (from toxin buildup)
These symptoms are not specific to CKF alone and can occur with other diseases, so medical evaluation is always necessary.
How is Chronic Kidney Failure diagnosed?
CKF is diagnosed by combining the symptoms described above with a blood chemistry panel and sometimes imaging tests such as a kidney ultrasound. In blood tests, two molecules — creatinine and urea — are often elevated in CKF patients because they are waste products that the kidneys normally eliminate through urine. Elevated creatinine and urea indicate that the kidneys are not functioning properly. There may also be anemia due to lack of erythropoietin. Calcium and phosphorus are also altered. Imaging may show smaller kidneys or poor differentiation between kidney cortex and medulla.
How do I interpret my blood test results?
A blood chemistry panel measures chemical substances in the blood. In the context of CKF, important substances include urea, creatinine, uric acid, potassium, calcium, phosphorus, and albumin. If some of these are elevated in the blood, it confirms that the kidneys are not working properly.
Example:
A 60-year-old man with a history of high blood pressure and diabetes has not monitored his sugar or blood pressure. He notices swelling in legs and face, reduced urination, and fatigue. Blood tests show abnormal values, including high creatinine, urea, and phosphorus — consistent with chronic kidney failure:
Results Normal Reference Ranges
-
Glucose: 250 mg/dl. 70 - 120 mg/dl.
-
Urea: 100 mg/dl. 20 - 50 mg/dl.
-
Creatinine: 1.7 mg/dl. 0.6 - 1.1 mg/dl.
-
Na (Sodium): 135 meq/l. 135 - 145 meq/l.
-
K (Potassium): 4.5 meq/l. 3.5 - 5 meq/l.
-
Calcium: 9 mg/l. 8 – 12 mg/l.
-
P (Phosphorus): 5 mg/dl. 1 - 4.5 mg/dl.
-
Albumin: 3 gr/dl. 3.8 – 4.6 gr/dl.
*mg/dl: milligrams per deciliter
meq/l: milliequivalentes per liter
gr/dl: grams per deciliter


kidney replacement therapies:
peritoneal dialysis, hemodialysis
or renal transplant

medication

diet
How is Chronic Kidney Failure treated?



DIET
Diet is critically important. Ideally, protein intake should be 0.6 - 0.8 grams per kilogram of body weight per day.
Sodium should be 2 grams per day or less, with foods low in phosphorus and often low in potassium.
Working with a dietitian specialized in renal diets is usually necessary.
MEDICATION
Depending on the patient’s condition, health problems, and lab results, various medications may be prescribed, including drugs for:
-
High blood pressure
-
Anemia
-
High phosphorus
-
Diabetes
-
High uric acid, cholesterol, or triglycerides
-
Metabolic acidosis
-
High potassium
-
Newer drugs to slow (not cure) established kidney damage
This is why follow-up with your specialist physician is so important.
KIDNEY REPLACEMENT THERAPIES
When kidneys function at less than 15% capacity, toxins and fluid build up, and dialysis is usually needed. There are two main forms::
-
Peritoneal dialysis: a catheter is placed in the abdomen and special fluid removes toxins and excess fluid
-
Hemodialysis: a catheter is placed in a large vein, and a machine filters blood for about 3 hours per session, typically three times a week for life.
The goal of hemodialysis is to keep the patient alive while waiting for a kidney transplant [see Ref. 2]
The best long-term replacement therapy is a kidney transplant, either from a compatible living donor or a deceased donor.
Complications of kidney replacement therapies
Peritoneal dialysis: The most frequent complication is peritonitis (infection of the abdominal cavity), often requiring hospitalization and reducing the effectiveness of peritoneal dialysis.
Hemodialysis: The main complication is anemia, often requiring blood transfusions.
Kidney transplant: A possible complication is rejection of the transplanted kidney, and transplant recipients must take lifelong immunosuppressive medications to avoid or treat rejection.
Unfortunately, there are not enough kidneys available worldwide for transplant, and wait lists continue to grow.
Can I have Chronic Kidney Failure without dialysis?
Strictly speaking, yes. If your kidneys still function above 15%, you can follow a renal diet, your toxins in blood do not accumulate excessively, you are not significantly swollen, and you still urinate, you may be a candidate for conservative medical treatment (medications that help the kidneys and body perform functions the kidneys can no longer do). However, if GFR drops to around 5–7 mL/min/1.73m², dialysis may become imminent.
Are there new treatments for CKF?
Recent clinical studies show benefits of two families of medications:
a) SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin), originally used for diabetes, have additional benefits in patients with CKD, and are recommended for patients with GFR > 20 mL/min/1.73m² (Stage 4) slowing disease progression by 36% as shown in major clinical trials [see Ref. 3-5].
b) Non-steroidal mineralocorticoid receptor antagonists such as finerenone, recommended for patients with GFR > 25 mL/min/1.73m² (Stage 4) [see Ref. 6]
The KDIGO organization’s 2024 clinical practice guideline includes these medications among those that slow kidney function loss.
In summary, throughout history there have been four groups of medications for CKD that, according to the recommendations issued by KDIGO, slow the loss of kidney function:
-
Medications used to treat high blood pressure, known as ACE inhibitors (ACEIs) and ARBs
-
The more recently discovered SGLT2 inhibitors
-
Non-steroidal mineralocorticoid receptor antagonists
-
GLP-1 receptor agonists
Not new, but very important—and sometimes underused—is supplementation with sodium bicarbonate in patients with metabolic acidosis. Metabolic acidosis begins when the eGFR is below 60 mL/min/1.73 m² and becomes extremely common in patients with an eGFR below 30 mL/min/1.73 m², that is, those with stage 4 and stage 5 kidney failure.
Apparently, and taking into account the KDIGO 2024 guidelines, this encompasses everything that currently exists to treat patients with CKD. Ultimately, those patients who progress to stage 5 with an eGFR below 15 mL/min/1.73 m² will be referred for renal replacement therapy with dialysis, hemodialysis, or kidney transplantation. There will also be patients who choose not to undergo any of these replacement therapies and will instead be treated with palliative measures.

Intermediate Metabolites
of the Krebs Cycle
A newer option in the literature is supplementation with intermediate metabolites of the Krebs cycle combined with calcium phosphate binders and sodium bicarbonate, which has been reported to increase and improve estimated GFR in patients with CKD Stages 3b, 4, and 5, suggesting it may be another tool for managing this disease.
Metabolites are organic compounds that the body naturally produces and are vitally important in the Krebs cycle, also known as the citric acid cycle. This cycle helps the body form proteins, which are essential for nutrition, and generate energy. In recent studies involving patients with kidney disease, these metabolites have been reported to be helpful or to serve as another tool for managing this condition.
Cited References
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. https://www.nejm.org/doi/full/10.1056/NEJMoa011161
-
Hernández-Usero, Alcaraz V, Sánchez-Pozo A. ¿Es suficiente la hemodiálisis para el mantenimiento de los enfermos con insuficiencia renal crónica? Ars Pharmaceutica. 1997;38(1):5-14.
-
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24): 2295-2306. https://www.nejm.org/doi/full/10.1056/NEJMoa1811744
-
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1445. https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
-
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-126. https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
-
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
-
Hernández-Miramontes JA, Méndez-Durán A, Hernández-Villanueva JA. Tricarboxylic cycle intermediates in combination with calcium phosphate chelators and sodium bicarbonate increase eGFR in patients with stages 3b, 4 and 5 CKD: a retrospective observational study. Rev Colomb Nefrol. 2024;11(2):1-18. https://revistanefrologia.org/index.php/rcn/article/view/778/1115
-
Hernández-Miramontes JA, Hernández-Villanueva JA, Pacifuentes-Orozco A, Méndez-Durán A. Ácidos carboxílicos en combinación con quelantes cálcicos de fósforo y bicarbonato de sodio para el tratamiento de la uremia e hiperfosfatemia en pacientes con ERC estadios 3, 4 y 5. Gac Med Bilbao. 2019;116(3):104-109. https://gacetamedicabilbao.eus/index.php/gacetamedicabilbao/article/view/707